Parkinson's DiseaseNCT02906488
Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease
An observational study of Parkinson's Disease, run by AbbVie at 127 sites in Japan.
Trial summary
The purpose of this study is to assess the safety and efficacy of long-term use of Duodopa in patients with Parkinkon's disease in actual usage Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Parkinson's Disease
- How many people
- 839 participants
- Where
- 127 sitesJapan
- Study dates
- 12 Sep 2016to 24 Jul 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with Parkinson's disease using Duodopa for the purpose of improving circadian change (wearing-off phenomenon) of symptoms of Parkinson's disease in which sufficient effect cannot be obtained with existing drug therapy including levodopa-containing drugs.
Who may be able to join
- 1. Patients with Parkinson's disease using Duodopa for the purpose of improving circadian change (wearing-off phenomenon) of symptoms of Parkinson's disease in which sufficient effect cannot be obtained with existing drug therapy including levodopa-containing drugs.
Who cannot join
- NA
Trial locations and contacts
127 sites in 1 country.
127 sites in 1 country
Japan127 sites
Saitama Rihabilitation Center /ID# 168356
Ageo-shi, Saitama, 362-0057
Minami Kyushu National Hospital /ID# 171052
Aira-shi, Kagoshima-ken, 899-5241
Akita City Hospital /ID# 207121
Akita, Akita, 010-0933
Aomori Prefectural Central Hospital /ID# 165286
Aomori, Aomori, 030-8553
Japanese Red Cross Asahikawa Hospital /ID# 207149
Asahikawa-shi, Hokkaido, 070-0061
National Hospital Organization Asahikawa Medical Center /ID# 155744
Asahikawa-shi, Hokkaido, 070-8644
Japanese Red Cross Ashikaga Hospital /ID# 210476
Ashikaga-shi, Tochigi, 326-0843
Juntendo University Hospital /ID# 160823
Bunkyo-ku, Tokyo, 113-8431
Nippon Medical School Hospital /ID# 204339
Bunkyo-ku, Tokyo, 113-8603
Nippon Medical School Hospital /ID# 207118
Bunkyo-ku, Tokyo, 113-8603
University of Yamanashi Hospital /ID# 207120
Chuo-shi, Yamanashi, 409-3898
Date Red Cross Hospital /ID# 207776
Date-shi, Hokkaido, 052-8511
Nanpuh Hospital /ID# 207128
Fujieda-shi, Shizuoka, 8928512
Fukui Red Cross Hospital /ID# 166907
Fukui-shi, Fukui, 918-8501
Fukuoka University Hospital /ID# 166900
Fukuoka, Fukuoka, 814-0180
Fukushima Medical University Hospital /ID# 169560
Fukushima, Fukushima, 960-1295
Gifu Municipal Hospital /ID# 207777
Gifu, Gifu, 500-8323
Gifu Prefectural General Medical Center /ID# 166894
Gifu, Gifu, 500-8727
Gifu University Hospital /ID# 207378
Gifu, Gifu, 501-1194
Hakodate Municipal Hospital /ID# 212304
Hakodate-shi, Hokkaido, 041-8680
Seirei Hamamatsu General Hospital /ID# 212266
Hamamatsu, Shizuoka, 430-8558
Higashiosaka City Medical Center /ID# 166901
Higashiosaka-shi, Osaka, 578-8588
Himeji Central Hospital /ID# 164136
Himeji-shi, Hyōgo, 672-8501
Hiroshima City Hiroshima Citizens Hospital /ID# 207126
Hiroshima, Hiroshima, 730-8518
Hiroshima Teishin Hospital /ID# 245072
Hiroshima, Hiroshima, 730-8798
Hiroshima University Hospital /ID# 212269
Hiroshima, Hiroshima, 734-8551
Ina Central Hospital /ID# 166905
Ina-shi, Nagano, 396-0033
Tokai University Hospital /ID# 250954
Isehara, Kanagawa, 259-1193
Mihara Memorial /ID# 252885
Isesaki-shi, Gunma, 372-0006
Izumi City General Hospital /ID# 207775
Izumi-shi, Osaka, 594-0073
Juntendo University Shizuoka Hospital /ID# 207133
Izunokuni-shi, Shizuoka, 410-2295
Kayashimaikuno Hospital /ID# 171051
Kadoma-shi, Osaka, 571-0071
Okatsu Hospital /ID# 213489
Kagoshima, Kagoshima-ken, 890-0067
Kagoshima University Hospital /ID# 166909
Kagoshima, Kagoshima-ken, 890-8520
Kameda General Hospital /ID# 166906
Kamogawa-shi, Chiba, 296-8602
Nara Medical University Hospital /ID# 160830
Kashihara-shi, Nara, 634-8522
NHO Niigata National Hospital /ID# 204337
Kashiwazaki-shi, Niigata, 945-8585
St Marianna University School Of Medicine /ID# 204347
Kawasaki-shi, Kanagawa, 216-8511
St Marianna University School Of Medicine /ID# 207119
Kawasaki-shi, Kanagawa, 216-8511
Kitakyushu Yahata Higashi Hospital /ID# 213849
Kitakyushu-shi, Fukuoka, 805-0061
Wakamatsu Hospital /ID# 160818
Kitakyusyu-shi, Fukuoka, 808-0024
Kobayashi City Hospital /ID# 208715
Kobayashi-shi, Miyazaki, 886-0004
Kobe Home Clinic of Neurology /ID# 212308
Kobe, Hyōgo, 650-0015
Kobe University Hospital /ID# 166895
Kobe, Hyōgo, 650-0017
Nishi-Kobe Medical Center /ID# 207781
Kobe, Hyōgo, 651-2273
National Center of Neurology and Psychiatry /ID# 160824
Kodaira-shi, Tokyo, 187-0031
Kumamoto Saishunso National Hospital /ID# 212813
Kōshi, Kumamoto, 861-1102
Juntendo Tokyo Koto Geriatric Medical Center /ID# 260157
Koto-ku, Tokyo, 136-0075
University Hospital Kyoto Prefectural University of Medicine /ID# 207130
Kyoto, Kyoto, 602-8566
Kyoto University Hospital /ID# 162891
Kyoto, Kyoto, 606-8507
National Hospital Organization Utano National Hospital /ID# 164139
Kyoto, Kyoto, 616-8255
NHO Matsue Medical Center /ID# 164135
Matsue, Shimane, 690-0015
Aizawa Hospital /ID# 212307
Matsumoto-shi, Nagano, 390-0814
Shinshu University Hospital /ID# 169559
Matsumoto-shi, Nagano, 390-8621
Saiseikai Matsuyama hospital /ID# 169561
Matsuyama, Ehime, 791-8026
Dokkyo Medical University Hospital /ID# 171050
Mibu, Tochigi, 321-0293
Kikuno Hospital /ID# 207784
Minamikyusyu-shi, Kagoshima-ken, 8970215
Mita Hospital /ID# 207210
Minato-ku, Tokyo, 108-8329
Mino City Hospital /ID# 161765
Minoh, Osaka, 562-0014
Fujimoto General Hospital /ID# 207150
Miyakonojo-shi, Miyazaki, 885-0055
Junwakai Memorial Hospital /ID# 164141
Miyazaki, 880-2112
Mino Tanaka Hospital /ID# 212272
Miyoshi-shi, Tokushima, 470-0224
Moka Chuo Clinic /ID# 213490
Mooka-shi, Tochigi, 321-4337
Iwate Medical University Uchimaru Medical Center /ID# 212265
Morioka, Iwate, 020-8505
Muroran-Clinic /ID# 207780
Muroran-shi, Hokkaido, 050-0074
Nagaoka Red Cross Hospital /ID# 212301
Nagaoka-shi, Niigata, 940-2085
Nagoya University Hospital /ID# 212303
Nagoya, Aichi-ken, 466-8560
Nagoya City University Hospital /ID# 166893
Nagoya, Aichi-ken, 467-8602
Nitobe Memorial Nakano General Hospital /ID# 207377
Nakano-ku, Tokyo, 164-0011
Kochi Medical School Hospital /ID# 166903
Nankoku-shi, Kochi, 783-8505
Midori Hospital /ID# 207127
Niigata, Niigata, 950-0983
Hyogo Medical University Hospital /ID# 169562
Nishinomiya-shi, Hyōgo, 663-8501
Nagasaki Kita Hospital /ID# 204353
Nishisonogi-gun, Nagasaki, 851-2103
Obihiro kosei Hospital /ID# 166904
Obihiro-shi, Hokkaido, 080-0024
Hokuto Hospital /ID# 207850
Obihiro-shi, Hokkaido, 080-0833
Oita Prefectural Hospital /ID# 208714
Ōita, Oita Prefecture, 870-0855
Japanese Red Cross Okayama Hospital /ID# 212268
Okayama, Okayama-ken, 700-8607
Okayama Kyokuto Hospital /ID# 166892
Okayama, Okayama-ken, 703-8265
Osaka Saiseikai Nakatsu Hospital /ID# 168357
Osaka, Osaka, 530-0012
Kitano Hospital, Tazuke Kofukai Medical Research Institute /ID# 259507
Osaka, Osaka, 530-8480
Japanese Red Cross Osaka Hospital /ID# 207123
Osaka, Osaka, 543-8555
Toho University Medical Center Omori Hospital /ID# 212271
Ōta-ku, Tokyo, 143-8541
SUBARU Health Insurance Society Ota Memorial Hospital /ID# 207778
Ota-shi, Gunma, 373-8585
Shiga University of Medical Science Hospital /ID# 212306
Ōtsu, Shiga, 520-2192
Ryugasaki Saiseikai Hospital /ID# 207846
Ryugasaki-shi, Ibaraki, 301-0854
National Hospital Organization Sagamihara National Hospital /ID# 160825
Sagamihara-shi, Kanagawa, 252-0392
Saiseikai Saijo Hospital /ID# 167705
Saijo-shi, Ehime, 793-0027
Jichi Medical University Saitama Medical Center /ID# 207181
Saitama-shi, Saitama, 330-8503
Kinki University Sakai Hospital /ID# 166908
Sakai-shi, Osaka, 590-0132
Nihonkai General Hospital /ID# 207196
Sakata-shi, Yamagata, 998-0828
Hyogo-Chuo National Hospital /ID# 207376
Sanda-shi, Hyōgo, 669-1592
Sapporo Medical University Hospital /ID# 207373
Sapporo, Hokkaido, 060-8543
Sapporo City General Hospital /ID# 212305
Sapporo, Hokkaido, 060-8604
Hokkaido University Hospital /ID# 166902
Sapporo, Hokkaido, 060-8648
Hokkaido Medical Center /ID# 161763
Sapporo, Hokkaido, 063-0005
Sapporo Neurology Hospital /ID# 207779
Sapporo, Hokkaido, 065-0021
Tohoku University Hospital /ID# 169557
Sendai, Miyagi, 9808574
NHO Sendai Nishitaga National Hospital /ID# 164977
Sendai, Miyagi, 982-8555
Tohoku Medical and Pharmaceuti /ID# 169558
Sendai, Miyagi, 983-0005
National Hospital Organization Sendai Medical Center /ID# 160831
Sendai, Miyagi, 983-8520
Japanese Red Cross Medical Center /ID# 207129
Shibuya-ku, Tokyo, 150-8935
Nanbu Medical Center / Nanbu Child Medical Center /ID# 207148
Shimajiri-gun, Okinawa, 901-1105
National Hospital Organization Kanmon Medical Center /ID# 207370
Shimonoseki-shi, Yamaguchi, 752-0985
Shingu Municipal Medical Center /ID# 207131
Shingu-shi, Wakayama, 647-0072
Keio University Hospital /ID# 212267
Shinjuku-ku, Tokyo, 160-8582
Tokyo Women's Medical University Hospital /ID# 204350
Shinjuku-ku, Tokyo, 162-8666
Tokuyama Central Hospital /ID# 171049
Shunan-shi, Yamaguchi, 745-8522
Kamiya Clinic /ID# 261328
Soka-shi, Saitama, 340-0017
The University of Osaka Hospital /ID# 161764
Suita-shi, Osaka, 565-0871
Tachikawa Hospital /ID# 207182
Tachikawa
National Hospital Organization Takasaki General Medical Center /ID# 207773
Takasaki-shi, Gunma, 370-0829
Hyogo College of Medicine Sasayama Medical Center /ID# 208716
Tanbasasayama-shi, Hyōgo, 669-2321
Itsuki Hospital /ID# 164138
Tokushima, Tokushima, 770-0852
Ehime University Hospital /ID# 162889
Toon-shi, Ehime, 791-0295
JA Toride Medical Center /ID# 212302
Toride-shi, Ibaraki, 302-0022
Toyooka Hospital /ID# 212270
Toyooka-shi, Hyōgo, 668-8501
Toyota Memorial Hospital /ID# 166891
Toyota-shi, Aichi-ken, 471-8513
Mie University Hospital /ID# 164140
Tsu, Mie-ken, 514-8507
Yamaguchi University Hospital /ID# 207774
Ube-shi, Yamaguchi, 755-8505
Juntendo University Urayasu Hospital /ID# 162890
Urayasu-shi, Chiba, 279-0021
Wakayama Medical University Hospital /ID# 160817
Wakayama, Wakayama, 641-8510
NHO Yanai Medical Center /ID# 164137
Yanai-shi, Yamaguchi, 742-1352
Yokohama City University Medical Center /ID# 165285
Yokohama, Kanagawa, 232-0024
Nomura Neuro Sleep Clinic /ID# 213491
Yonago-shi, Tottori, 683-0846
Tottori University Hospital /ID# 207124
Yonago-shi, Tottori, 683-8504
Minami Nara General Medical Center /ID# 207372
Yoshino-gun, Nara, 638-8551
National Hospital Organization Akita National Hospital /ID# 207374
Yurihonjo-shi, Akita, 018-1301
About this study
Official title: Special Drug Use Results Survey of Safety and Efficacy of Long-term (104 Weeks) Use of Duodopa Enteral Solution in Patients With Parkinson's Disease in Actual Usage Condition
The purpose of this study is to assess the safety and efficacy of long-term use of Duodopa in patients with Parkinkon's disease in actual usage
- Conditions
- Parkinson's Disease
- Keywords
- Quality of life
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with Parkinson's Disease | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in "Off" Periods From Start of Treatment to Week 104
"Off" periods describe those times when medication is not working well and a person has greater difficulty with movement.
Measured: 104 weeks
Secondary outcomes (5)
Time-dependent Change in "Off" Time and "On" Time Accompanied By Dyskinesia Interfering with Daily Activities
"Off" periods describe those times when medication is not working well and a person has greater difficulty with movement, and "On" periods describe when medication is working well and symptoms are controlled.
Measured: 104 Weeks
Time-dependent Change in Unified Parkinson's Disease Rating Scale (UPDRS)
Motor evaluation
Measured: 104 Weeks
Time-dependent Change in Parkinson's Disease Questionnaire - 8 Items (PDQ-8)
The PDQ-8 is a quality of life questionnaire for PD patient. This short-form version derived from the PDQ-39 includes 1 question from each of the domains on the PDQ-39 (mobility, ADLs, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort).
Measured: 104 weeks
"Off" Period and "On" Period Accompanied by Dyskenesia Interfering with Daily Activities by Patient Characteristic Factor
"Off" periods describe those times when medication is not working well and a person has greater difficulty with movement, and "On" periods describe when medication is working well and symptoms are controlled.
Measured: 104 weeks
Time-dependent Change in Parkinson's Disease Quality of Life Questionnaire - Carers (PDQ-Carer)
The PDQ-Carer is a 29 item measure of health related quality of life for use with carers of people with Parkinson's disease.
Measured: 104 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Sep 2016 (estimated)
- Study start12 Sep 2016
- Primary completion24 Jul 2025
- Study completion24 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson's DiseaseStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 839 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02906488
- Sponsor's protocol ID
- P15-720
- Status last verified
- Aug 2025
- First submitted
- 12 Sep 2016
- Last updated
- 24 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 24 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Special Drug Use Results Survey of Safety and Efficacy of Long-term (104 Weeks) Use of Duodopa Enteral Solution in Patients With Parkinson's Disease in Actual Usage Condition
- ClinicalTrials.gov ID
- NCT02906488
- Acronym / sponsor ID
- P15-720
- Conditions
- Parkinson's Disease
- Keywords
- Quality of life
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 839 participants (actual)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 12 Sep 2016 (actual)
- Primary completion
- 24 Jul 2025 (actual)
- Study completion
- 24 Jul 2025 (actual)
- First posted
- 20 Sep 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to assess the safety and efficacy of long-term use of Duodopa in patients with Parkinkon's disease in actual usage
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with Parkinson's Disease | – | – |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with Parkinson's disease using Duodopa for the purpose of improving circadian change (wearing-off phenomenon) of symptoms of Parkinson's disease in which sufficient effect cannot be obtained with existing drug therapy including levodopa-containing drugs.
Key inclusion criteria (1 listed)
- 1. Patients with Parkinson's disease using Duodopa for the purpose of improving circadian change (wearing-off phenomenon) of symptoms of Parkinson's disease in which sufficient effect cannot be obtained with existing drug therapy including levodopa-containing drugs.
Key exclusion criteria (1 listed)
- NA
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change in "Off" Periods From Start of Treatment to Week 104
Time frame: 104 weeks
"Off" periods describe those times when medication is not working well and a person has greater difficulty with movement.
5 secondary outcomes
Time-dependent Change in "Off" Time and "On" Time Accompanied By Dyskinesia Interfering with Daily Activities
Time frame: 104 Weeks
Time-dependent Change in Unified Parkinson's Disease Rating Scale (UPDRS)
Time frame: 104 Weeks
Time-dependent Change in Parkinson's Disease Questionnaire - 8 Items (PDQ-8)
Time frame: 104 weeks
"Off" Period and "On" Period Accompanied by Dyskenesia Interfering with Daily Activities by Patient Characteristic Factor
Time frame: 104 weeks
Time-dependent Change in Parkinson's Disease Quality of Life Questionnaire - Carers (PDQ-Carer)
Time frame: 104 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Aug 2025.
- Related Info.Link provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Parkinson's Disease
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Not yet recruiting
Compulsive Eating and Brain's Reward System in Different Pathologies
PARKINSON DISEASE (Disorder), Bipolar 1 Disorder
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ABBVIE INC. study director
AbbVie
127 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Parkinson's Disease, run by AbbVie at 127 sites in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 127 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in "Off" Periods From Start of Treatment to Week 104 (time frame: 104 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2025.